Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care-Reference-Cited by-同舟云学术

Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care

Published:2017-07-27 Issue:8 Volume:71 Page:e12979
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Descamps Olivier S.¹,Fraass Uwe²,Dent Ricardo³,März Winfried⁴⁵⁶,Gouni-Berthold Ioanna⁷

Affiliation:

1. Department of Internal Medicine; Centres Hospitaliers Jolimont; Haine Saint-Paul Belgium

2. Amgen GmbH; Munich Germany

3. Amgen (Europe) GmbH; Zug Switzerland

4. Clinical Institute of Medical and Chemical Laboratory Diagnostics; Medical University Graz; Graz Austria

5. Medical Clinic V (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology); Medical Faculty Mannheim; University of Heidelberg; Heidelberg Germany

6. Synlab Academy; Synlab Holding Deutschland GmbH; Mannheim and Augsburg Germany

7. Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP); University of Cologne; Cologne Germany

Funder

Amgen

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ijcp.12979/fullpdf

Reference81 articles.

1. Cardiovascular disease in Europe - epidemiological update 2015;Townsend;Eur Heart J,2015

2. World Health Organization Cardiovascular diseases (CVDs) 2015 http://www.who.int/mediacentre/factsheets/fs317/en/

3. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR);Piepoli;Eur Heart J,2016

4. Cardiovascular risk factors. Insights from Framingham Heart Study;O'Donnell;Rev Esp Cardiol,2008

5. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent;Lancet,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vitro and In Vivo;International Journal of Molecular Sciences;2021-12-01

2. Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy;Journal of Cardiovascular Translational Research;2021-08-31

3. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome;Current Vascular Pharmacology;2021-03-23

4. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials;Journal of Diabetes & Metabolic Disorders;2020-06-01

5. PCSK9 inhibitors and cardiovascular outcomes;Expert Opinion on Biological Therapy;2019-10-18